PURE Bioscience to Present at the 30th Annual ROTH Capital Partners Conference

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that the Company will present at the 30th Annual ROTH Capital Partners Conference on March 12, 2018 in Orange County, CA.

Hank R. Lambert, CEO, will present on March 12^th at 9:00am PT and provide business updates on the Company’s two SDC-based food safety solutions (test results consistently demonstrate superior pathogen reductions versus other antimicrobials in use in the food industry):

• PURE® Hard Surface (EPA approved food contact surface disinfectant)
  • Customers include Chipotle Mexican Grill, Subway and other restaurant chains; expanding use with +70 national food processors
  • Recent initial sales made into food transportation market (refrigerated trucks and plastic pallets)
• PURE Control® (FDA and USDA approved direct food contact processing aid)
  • Produce - first customer Taylor Farms; 3 other processors ongoing validation work
  • Poultry - USDA approved for raw poultry parts processing; ongoing in-plant validation trials
    • Ongoing work to gain USDA approval for whole bird OLR (online reprocessing)

The presentation will be webcast live with slides (and available for replay) and can be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/.

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2017 and Form 10-Q for the first fiscal quarter ended October 31, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180227006322/en/

PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext.103
[email protected]
or
Bibicoff + MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
[email protected]
or
Redwood Investment Group
Tom Hemingway
714-978-4425
[email protected]